{
    "nctId": "NCT00645333",
    "briefTitle": "Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer",
    "officialTitle": "Phase I/II Trial of MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer: A Study by the Stem Cell Clinical Consortium",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Dose Limiting Toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Men or women with metastatic (Stage IV) breast cancer, or with locally advanced breast cancer (Stages IIIA \\> 10 cm, or Stages IIIB and IIIC) that did not respond to first-line anthracycline-based chemotherapy, for whom docetaxel is a recommended therapy\n* Presence of measurable or evaluable disease\n* Adequate organ function\n* Ability to swallow intact study drug capsules\n* Zubrod Performance Status of 0-1 with at least a 3 month life expectancy\n* Appropriate time must have elapsed since prior anti-neoplastic therapy with resolution of acute toxicity\n\nExclusion Criteria:\n\n* Concurrent treatment with hormonal therapy intended to treat cancer\n* Radiotherapy within 7 days prior to first dose\n* Symptomatic central nervous system, and/or epidural metastases or symptomatic carcinomatous meningitis or with radiation treatment completed within the past 8 weeks\n* Serious comorbid illness which will limit the ability of the patient to safely receive anticancer treatment\n* Patients who are pregnant or nursing\n* Confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}